Title : Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.

Pub. Date : 2020 Oct

PMID : 32378049






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lapatinib (Lap), a dual kinase inhibitor of HER2 and epidermal growth factor receptor is used in the treatment of advanced HER-2 positive breast cancers and is currently being evaluated in the adjuvant setting. Lapatinib epidermal growth factor receptor Homo sapiens
2 Lapatinib (Lap), a dual kinase inhibitor of HER2 and epidermal growth factor receptor is used in the treatment of advanced HER-2 positive breast cancers and is currently being evaluated in the adjuvant setting. Lapatinib epidermal growth factor receptor Homo sapiens